1. Anti-melanogenic effects of resorcinol are mediated by suppression of cAMP signaling and activation of p38 MAPK signaling.
- Author
-
Kang M, Park SH, Oh SW, Lee SE, Yoo JA, Nho YH, Lee S, Han BS, Cho JY, and Lee J
- Subjects
- Animals, Cell Line, Tumor, Cells, Cultured, Drug Interactions, Enzyme Activation, Gene Expression drug effects, Humans, Imidazoles pharmacology, Indoles metabolism, Intramolecular Oxidoreductases genetics, Melanins metabolism, Melanocytes drug effects, Melanocytes metabolism, Melanosis drug therapy, Melanosis genetics, Membrane Glycoproteins genetics, Mice, Microphthalmia-Associated Transcription Factor genetics, Monophenol Monooxygenase antagonists & inhibitors, Monophenol Monooxygenase metabolism, Oxidoreductases genetics, Phosphorylation, Pyridines pharmacology, Real-Time Polymerase Chain Reaction, Resorcinols therapeutic use, Cyclic AMP metabolism, Indoles antagonists & inhibitors, MAP Kinase Signaling System drug effects, Resorcinols pharmacology, p38 Mitogen-Activated Protein Kinases metabolism
- Abstract
In this study, we investigated the inhibitory mechanisms of resorcinol in B16F10 mouse melanoma cells. We found that resorcinol reduced both the melanin content and tyrosinase activity in these cells. In addition, resorcinol suppressed the expression of melanogenic gene microphthalmia-associated transcriptional factor (MITF) and its downstream target genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2. In addition, we found that resorcinol reduced intracellular cAMP levels and protein kinase A (PKA) activity, and increased phosphorylation of the p38 mitogen-activated protein kinase (MAPK). Resorcinol was also found to directly inhibit tyrosinase activity. However, resorcinol-induced decrease in melanin content, tyrosinase activity, and tyrosinase protein levels were attenuated by SB203580, a p38 MAPK inhibitor. Taken together, these data indicate that anti-melanogenic activity of resorcinol is be mediated through the inhibition of cAMP signaling and activation of p38 MAPK, indicating that resorcinol may be a possible ameliorating agent in the treatment of hyperpigmentation skin disorders.
- Published
- 2018
- Full Text
- View/download PDF